Physician profile
Tamara Young
NPI 1558722983
$2,063.12
in general payments reported to CMS, 2019-2025
21 companies · $828 in 2025
The $828 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $211 · 2023: $345 · 2024: $509 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617 · Education: $65.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.92 |
| Education | $65.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $604.58 | 2022-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $235.01 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $223.72 | 2021-2024 | Hyqvia, Takhzyro, Cuvitru |
| Genzyme Corporation | $137.71 | 2023-2025 | |
| Csl Behring | $129.29 | 2021-2025 | Haegarda, Kcentra, Hizentra |
| Genentech USA, INC. | $117.92 | 2023-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $104.14 | 2025 | |
| Glaxosmithkline, LLC. | $101.42 | 2021-2023 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $56.07 | 2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $50.97 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $49.45 | 2021 | |
| Kaleo, INC. | $48.20 | 2021-2023 | Auvi-Q |
| Pfizer INC. | $45.72 | 2021-2025 | |
| Organon LLC | $26.05 | 2025 | |
| Inspire Medical Systems, INC. | $23.45 | 2024 | Inspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $21.03 | 2021 | |
| Galderma Laboratories, L.P. | $20.16 | 2025 | Nemluvio |
| Baxter Healthcare | $18.99 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Biocryst US Sales Co., LLC | $18.87 | 2021 | |
| Grifols USA, LLC | $17.55 | 2022 | |
| Incyte Corporation | $12.82 | 2023 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.